Considerations for the development of therapeutic monoclonal antibodies.
about
mAbs: a business perspectiveUnderstanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical RelevanceImproving biophysical properties of a bispecific antibody scaffold to aid developabilityStructure-based prediction of asparagine and aspartate degradation sites in antibody variable regionsA novel antibody humanization method based on epitopes scanning and molecular dynamics simulationMining human antibody repertoires.Capturing the natural diversity of the human antibody response against vaccinia virusControl of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysAntibody-based therapy of leukaemia.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Review on modeling anti-antibody responses to monoclonal antibodies.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use.Epitope analysis of the rat dipeptidyl peptidase IV monoclonal antibody 6A3 that blocks pericellular fibronectin-mediated cancer cell adhesion.Computationally driven antibody engineering enables simultaneous humanization and thermostabilization.Biosimilars 2.0: guiding principles for a global "patients first" standard.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.Construction and characterization of a novel chimeric antibody c3C7 specific for the integrin αIIbβ3 complex.
P2860
Q24653360-6B21C210-C3AB-4EC1-A137-DB5078625BE3Q26747193-5F251108-2DF8-4984-8A19-C15241C08A65Q27679445-8801B70D-0084-4B14-AB0D-CD6DBB3D3D66Q28539968-DE5815D4-CD68-447D-A07E-38A9C8E97D81Q31144470-723451DE-50FB-4866-BA50-F21279B9F5BCQ33588489-4E185578-BEFF-49EC-98ED-82F0EC9AB233Q34529713-FE846189-923A-42F1-9C52-50F624AF51D8Q35149457-B87BBA27-025D-4442-AC96-4AA02C9016A2Q35888359-C83B3EC1-A06B-407A-BF62-AD904324A792Q37295534-DF9F5B70-7906-48E2-890F-868B95ED4548Q37605247-C5260B8D-8118-407F-BF4F-A51C32A1BD8EQ37854644-27B59D79-5E2E-4952-8092-D778BBAE0C94Q38229813-BA233B17-D2E3-4737-88B2-26F81E145288Q38364547-3C8EE0B1-5578-4F21-9C2E-CC9D4B880C97Q39558396-9D9062B2-8592-4172-A035-3B4869A0E18DQ39791473-3002EB41-67D8-41B2-B02C-D9B273FE39F9Q41656698-87A1AA1E-C81E-4184-B842-493EAB870498Q41835516-128F1B8C-7416-4342-AB64-73E1D9FE4CC5Q42869354-D962B818-4675-4BC4-8824-FBEB3927BA50Q43072108-7CB145A0-E7E2-4AFE-A23B-EB4846DF4909Q51021473-C1AD574C-D58B-44DB-9A63-2D88A1ED8CA7Q51751592-224B4AEC-23DE-40B1-9825-1C9BE33E37B3
P2860
Considerations for the development of therapeutic monoclonal antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Considerations for the development of therapeutic monoclonal antibodies.
@en
Considerations for the development of therapeutic monoclonal antibodies.
@nl
type
label
Considerations for the development of therapeutic monoclonal antibodies.
@en
Considerations for the development of therapeutic monoclonal antibodies.
@nl
prefLabel
Considerations for the development of therapeutic monoclonal antibodies.
@en
Considerations for the development of therapeutic monoclonal antibodies.
@nl
P2093
P1476
Considerations for the development of therapeutic monoclonal antibodies.
@en
P2093
Barbara L Rellahan
Kathleen A Clouse
Marjorie A Shapiro
Mate Tolnay
Patrick G Swann
Subramanian Muthukkumar
P304
P356
10.1016/J.COI.2008.05.013
P577
2008-07-02T00:00:00Z